Patents Assigned to AstraZeneca
  • New Salt I
    Publication number: 20080227817
    Abstract: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide benzoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.
    Type: Application
    Filed: July 31, 2006
    Publication date: September 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Julien Giovannini, Bo-Goran Josefsson
  • Peptides as Biomarkers of Copd
    Publication number: 20080227117
    Abstract: The present invention relates to the identification of biomarkers for the disease condition COPD. The uses of such biomarkers in diagnosis and therapy and a novel method for their identification is are also described.
    Type: Application
    Filed: April 27, 2006
    Publication date: September 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Thomas Fehniger, Claes Lindberg, Gyorgy Marko-Varga, Per Broberg
  • Compounds and uses thereof
    Patent number: 7425556
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: September 16, 2008
    Assignee: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Thioxanthine derivatives as myeloperoxidase inhibitors
    Patent number: 7425560
    Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: September 16, 2008
    Assignee: AstraZeneca AB
    Inventor: Anna-Karin Tidén
  • Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
    Publication number: 20080221063
    Abstract: The invention relates to heterocyclic derivatives of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1 is hydrogen or C1-3alkyl; R2 is selected from hydroxy, C1-5alkyl, carboxy, cyano, tetrazolyl, N—C1-5alkyltetrazolyl, oxazolyl, C1-5oxazolyl, isoxazolyl, C1-5 isoxazolyl, hydroxyC1-5alkyl, carboxy C1-5alkyl, C1-5alkoxyoxo C1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di(C1-5alkyl)carbamoyl, C1-5alkylcarbamoyl C1-4alkyl, hydroxy C1-5alkylcarbamoyl, C1-5alkoxy C1-5alkylcarbamoyl; —C1-5alkyl-Y1, —COOCHR17R18 and —CONR17R18; and R3 is hydrogen or halogen; or a pharmaceutically acceptable salt thereof, said compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals.
    Type: Application
    Filed: July 5, 2006
    Publication date: September 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Christer Alstermark, Kjell Andersson, Ulf Fahlander, Kenneth Granberg
  • CHEMICAL PROCESS
    Publication number: 20080221322
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Euan Alexander Arnott, John Crosby, Mathew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
  • Therapeutic Agents
    Publication number: 20080221107
    Abstract: Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.
    Type: Application
    Filed: July 13, 2006
    Publication date: September 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Fabrizio Giordanetto, Tord Inghardt, Peter Nordberg
  • New Benzimidazole Derivatives
    Publication number: 20080221188
    Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.
    Type: Application
    Filed: August 9, 2007
    Publication date: September 11, 2008
    Applicant: AstraZeneca R&D Sodertalje
    Inventors: William Brown, Shawn Johnstone, Denis Labrecque
  • Novel Pyrrolo [3,2-D]Pyrimidin-4-One Derivatives And Their Use In Therapy
    Publication number: 20080221136
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Application
    Filed: December 5, 2005
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
  • Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof
    Publication number: 20080221178
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3 and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: September 24, 2004
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Ziping Liu, Claire Milburn, Daniel Page, Christopher Walpole, Hua Yang
  • Novel 2-Heteroaryl Substituted Benzothiophenes and Benzofuranes 709
    Publication number: 20080221149
    Abstract: The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Application
    Filed: March 5, 2008
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
  • Compounds
    Publication number: 20080221133
    Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.
    Type: Application
    Filed: June 1, 2007
    Publication date: September 11, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Anna-Karin Tiden
  • Ethanolamine Salt of N- (3-Methoxy-5-Methylpyrazin-2Yl) -2- (4-[1, 3, 4-Oxadiazole-2-Yl] Phenyl) Pyridine-3-Sulphonamide
    Publication number: 20080221124
    Abstract: N-(Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt its synthesis and its uses are described.
    Type: Application
    Filed: July 17, 2006
    Publication date: September 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Catherine Good, Phillip Hogan, Frank Montgomery
  • Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
    Patent number: 7423012
    Abstract: The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: September 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Marcel Linschoten, Magnus Polla
  • Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates
    Patent number: 7423154
    Abstract: An asymmetric synthesis of diarylmethylpiperazines is described. The synthetic route enables preparation of a variety of enatiomerically pure amines with different N-alkyl groups. The invention includes an asymmetric addition of organometallic compounds to chiral sulfinimine to give adducts in predominantly one diastereomer can subsequently be transferred into pure enantiomers of by cleavage of the chiral auxilliary which is followed by synthesis of the piperazine ring by alkylation procedures.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: September 9, 2008
    Assignee: AstraZeneca AB
    Inventors: William Brown, Niklas Plobeck
  • Substitute thiophenes and uses thereof
    Patent number: 7423061
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu
  • Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands
    Publication number: 20080214605
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: September 19, 2006
    Publication date: September 4, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Gerard M. Koether, Cristobal Alhambra, James Kang, Thomas R. Simpson, James Woods, Yan Li
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Publication number: 20080214812
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: May 8, 2008
    Publication date: September 4, 2008
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Therapeutic Agents
    Publication number: 20080214570
    Abstract: The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 3, 2006
    Publication date: September 4, 2008
    Applicant: ASTRAZENECA AB
    Inventors: James R. Empfield, Michael Laplante, Megan Murphy King
  • New Compounds 320
    Publication number: 20080214577
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: June 11, 2007
    Publication date: September 4, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Ltd
    Inventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Karin Kolmodin, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam